Skip to main content
Fig. 1 | Thrombosis Journal

Fig. 1

From: Comparison of the efficacy and safety of rivaroxaban and low-molecular-weight heparin in Chinese lung cancer patients with nonhigh-risk pulmonary embolism

Fig. 1

Cumulative incidence of (A) composite outcome of VTE recurrence or major bleeding, B all-cause mortality, C VTE recurrence, D major bleeding, and (E) CRNMB with rivaroxaban versus LMWH by propensity score-matched analysis. Abbreviations: LMWH, low-molecular-weight heparin; Riva, rivaroxaban; HR, hazard ratio; CI: confidence interval; VTE, venous thromboembolism; CRNMB, clinically relevant non-major bleeding

Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us